Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors

Nature·Jun 29

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Researchers are exploring the potential of repurposing certain inhibitors, including PARP inhibitors, as treatments for SARS-CoV-2. Studies are using computational design and other methods to investigate the effectiveness of various compounds against the virus. The search for effective antiviral treatments is ongoing, with scientists examining different approaches and mechanisms to combat COVID-19.

Full coverage

Antiviral drug discovery and development: challenges and future directions | Signal Transduction and Targeted Therapy

Nature·Feb 25

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

ACS Publications·Apr 15

Synthesis and in silico inhibitory action studies of azo-anchored imidazo[4,5-b]indole scaffolds against the COVID-19 main protease (Mpro) | Scientific Reports

Nature·May 6

Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing

Nature·Mar 11